Endocyte Inc. | Ownership
Companies that own Endocyte Inc.
venBio Select Advisor LLC
5,695,200
8.13%
0
3.83%
06/30/2018
RA Capital Management LLC
5,649,884
8.07%
1,768,091
6.15%
06/30/2018
BlackRock Fund Advisors
4,849,327
6.93%
3,147,395
0.01%
06/30/2018
VHCP Management LLC
4,300,000
6.14%
0
21.91%
06/30/2018
Partner Fund Management LP
4,100,953
5.86%
-266,495
1.4%
06/30/2018
The Vanguard Group, Inc.
3,005,603
4.29%
639,956
0%
06/30/2018
T. Rowe Price Associates, Inc.
2,619,809
3.74%
-489,991
0.01%
06/30/2018
Deerfield Management Company LP
2,324,299
3.32%
-303,241
1.31%
06/30/2018
Baker Bros. Advisors LP
2,277,799
3.25%
0
0.28%
06/30/2018
Citadel Advisors LLC
2,001,395
2.86%
1,540,258
0.05%
06/30/2018
| Address |
3000 Kent Avenue
West Lafayette Indiana 47906
United States
|
|
Employees
|
- |
| Website |
http://www.endocyte.com |
| Updated |
09/14/2018 |
| Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. |
